Scientists: Novel TB drug combo passes first test

July 23, 2012 by LAURAN NEERGAARD

Scientists are hot on the trail of a new tuberculosis treatment that a small study suggests might one day offer an alternative to battle this deadly lung disease, even if it is resistant to today's two main drugs.

There have not been new medications to treat TB in four decades. But the experimental three-, revealed Monday at the International AIDS Conference, is one of a list of promising compounds under intense testing around the world.

"We are cautiously optimistic that we are at the dawn of a new era for ," Dr. Diane Havlir of the University of California, San Francisco, who is co-chairing the meeting, told The Associated Press. She wasn't involved with the new research.

TB is one of the world's oldest killers, and every year it claims the lives of more than 1.5 million people, mostly in developing countries. It's also the leading killer of people with AIDS.

Standard first-line treatment requires taking four medications for six months. A frightening factor is that the bacteria that cause TB are fast becoming impervious to the two main drugs in that cocktail. The estimates there are more than 650,000 cases of multidrug-resistant TB a year. Treating -resistant TB can take more than two years, if it works at all.

Enter the new drug research.

Scientists in South Africa divided 85 newly diagnosed to take a variety of combinations of standard or experimental TB drugs,

Fifteen of the patients received a unique trio that emerged as the study's focus: An experimental antibiotic code-named PA-824, along with the pneumonia drug moxifloxacin and an older TB drug, .

In a two-week test, the drug trio killed at least as much of the that patients coughed up as today's standard four-drug therapy, and possibly worked a bit faster, said Dr. Mel Spigelam of the nonprofit TB Alliance, the Global Alliance for TB Drug Development.

That does not mean patients were cured in two weeks, stressed lead researcher Dr. Andreas Diacon of South Africa's Stellenbosch University. It takes longer to get the last TB bugs lurking deep in the lungs — the reason that TB therapy must be taken for months — but a two-week test is a standard first step in drug development.

It is noteworthy that the experimental combination doesn't include either of the two standard TB drugs — isoniazid and rifampicin — that today cause most problems of drug resistance. If additional research proves the drug trio really works, it could offer a much-needed alternative for multidrug-resistant TB as well, Spigelman said. Plus, it might be helpful for HIV patients who have trouble with today's TB treatments interacting badly with their anti-AIDS medicines.

A larger study has begun in South Africa, Tanzania and Brazil that will test how patients fare over two months. Monday's study, funded by the Bill and Melinda Gates Foundation and other groups, also was reported in the journal Lancet.

As important, the study showed a new way to research TB treatments that scientists hope will cut years off the lengthy process, said Mario Raviglione of the World Health Organization. Today, possible new drugs are tested simply by adding them onto standard treatment rather the TB Alliance approach of testing novel combinations from the beginning.

A few other promising TB drugs are further along in the pipeline. Johnson & Johnson recently filed for U.S. approval of its bedaquiline, which it hopes will become the first medicine specifically designated to treat multidrug-resistant TB. In a late-stage study this autumn, the company will test whether it can shorten therapy time for those especially hard-to-treat . And Otsuka Pharmaceutical Co. is studying its own drug, named delamanid.

Explore further: Trial for new drug-resistant TB treatment to begin

shares

Related Stories

Trial for new drug-resistant TB treatment to begin

March 19, 2012

A global health alliance Monday unveiled plans for the first clinical tests of a new treatment regimen for tuberculosis, including for patients with resistance to existing multidrug programs.

Trial signals major milestone in hunt for new TB drugs

July 23, 2012

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two ...

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.